Free tool
FAERS Monitor: Desonide
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017426 or its brand name (Desonide, Desonide). Reports on generic versions are filed under their own applications.
Reports
5,063
Serious
2,770
55% of reports
Hospitalization
1,116
Death reported
196
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,209
- macular degeneration787
- off label use428
- pain394
- nausea381
- pruritus361
- rash339
- headache327
- erythema317
- pyrexia307
- psoriasis284
- malaise283
- weight decreased278
- therapeutic product effect incomplete264
- dermatitis atopic250
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 14 |
| 2006 | 21 |
| 2007 | 14 |
| 2008 | 24 |
| 2009 | 35 |
| 2010 | 27 |
| 2011 | 51 |
| 2012 | 75 |
| 2013 | 110 |
| 2014 | 113 |
| 2015 | 216 |
| 2016 | 277 |
| 2017 | 248 |
| 2018 | 296 |
| 2019 | 279 |
| 2020 | 341 |
| 2021 | 619 |
| 2022 | 508 |
| 2023 | 579 |
| 2024 | 405 |
| 2025 | 460 |
| 2026 | 342 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,096 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| macular degenerationSignal | 787 | 292.9 | 274.0 | 213,753 |
| dermatitis atopicSignal | 250 | 19.8 | 17.5 | 4,430 |
| therapeutic product effect incompleteSignal | 264 | 15.5 | 13.8 | 3,558 |
| psoriasisSignal | 284 | 9.1 | 8.1 | 2,034 |
| erythemaSignal | 317 | 6.4 | 5.8 | 1,455 |
| weight decreasedSignal | 278 | 4.1 | 3.7 | 667 |
| pruritusSignal | 361 | 3.9 | 3.5 | 791 |
| drug ineffectiveSignal | 1,209 | 3.8 | 3.6 | 2,672 |
| pyrexiaSignal | 307 | 3.7 | 3.3 | 608 |
| rashSignal | 339 | 3.2 | 2.9 | 531 |
| malaiseSignal | 283 | 2.7 | 2.4 | 303 |
| painSignal | 394 | 2.7 | 2.4 | 420 |
| headacheSignal | 327 | 2.2 | 2.0 | 211 |
| off label useSignal | 428 | 2.0 | 1.9 | 233 |
| nauseaSignal | 381 | 2.0 | 1.8 | 197 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.